BRIDGEWATER, N.J., Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 7, 2018.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com.
To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers). The conference ID is 3488019.
A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404) 537-3406 (international callers). The access code for the replay is 3488019
The Company also announced that it expects to report its fourth quarter 2018 financial results on Thursday, February 28, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on February 28, 2019.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company markets a portfolio of branded pharmaceutical products through its Impax Specialty Pharma division focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.
Investor Relations and Corporate Communications
SOURCE Amneal Pharmaceuticals, Inc.